Answers are grounded in this paper and cite their sources.
Acute graft-versus-host disease (aGvHD) is a major cause of adverse outcome in hematopoietic stem cell transplantation (HSCT), with a high incidence (20-50%). A novel, non-invasive diagnostic test to predict for prevalence and severity would enable improved prophylaxis and reduce morbidity. Circulatory microRNAs miR-423, miR-199, miR-93* and miR-377 have previously been associated with aGvHD in post-HSCT patient plasma, but validation is lacking and their expression within extracellular vesicles (EVs) has not been explored. This study replicated elevated serum expression of miR-423 (p<0.001), miR-199 (p=0.04), miR-93* (p<0.001) and miR-377 (p=0.03) in aGvHD, using a prognostic cohort of day 14 (D14) post-HSCT patient samples (n=81). Expression also associated with disease severity. Further analysis at aGvHD diagnosis in an independent cohort (n=65) confirmed high miR-423 (p=0.02), miR-199 (p=0.007) and miR-93* (p=0.004) expression at disease onset. Investigation of expression patterns during early HSCT sequential timepoints (pre-HSCT to D28) identified elevated microRNAs at D7 post-HSCT in all transplant patients. In a novel investigation of microRNA expression in serum EVs (n=15), miR-423 (p=0.09), miR-199 (p=0.008) and miR-93* (p=0.001) levels were lower at D14 in patients who later developed aGvHD, and this was replicated for miR-423 (p=0.02) and miR-199 (p=0.04) (n=47). Comparing serum to circulating EVs, at D14 patients remaining aGvHD-free had higher expression of miR-423 (p=0.03), miR-199 (p<0.001) and miR-93* (p=0.001) in the EV fraction. Results verify the capacity for circulating miR-423, miR-199 and miR-93* as diagnostic and prognostic aGvHD biomarkers. The novel finding of their differential expression in EVs suggests a potential role in aGvHD etiology.
No takes yet. Share an insight, caveat, or question.
Crossland et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: